Health · Medical Research · 1 hr ago
Immune cells kill small cell lung cancer in lab tests
Researchers tested gamma delta T cells against small cell lung cancer, an aggressive disease in laboratory experiments.
Small cell lung cancer often evades the immune system, and fewer than 7 in 100 people survive for five years.
The team found that these immune cells killed cancer cells in the lab, and earlier trial data suggested patients with more of them in their tumors often responded better to treatment.
The cancer drug tarlatamab helped the cells get closer to their targets, while zoledronate, a drug used for bone disease, boosted their numbers and ability to detect the cancer.
The findings point to a possible new way to attack tumors that evade other immune cells, though any future treatment may not work for everyone.
Researchers say the levels of these immune cells and a tumor marker called BTN2A1 might help predict responses to immunotherapy.
Next, the work must move through animal studies and clinical trials before its potential for patients is known.
Researchers found that gamma delta T cells killed small cell lung cancer cells in laboratory tests.
The cells were more effective when combined with the drugs tarlatamab or zoledronate.
The approach aims to counter small cell lung cancer’s ability to evade the immune system.
The findings suggest the cells could offer a possible treatment strategy, but further research is needed before clinical trials.
- Who
- An international team of researchers studied gamma delta T cells.
- What
- The cells killed small cell lung cancer cells in lab tests, and two existing drugs enhanced their effectiveness.
- When
- The study was published on October 29, 2026.
- Where
- In laboratory tests; the research team included scientists from the Walter and Eliza Hall Institute of Medical Research in Australia.
- Why
- The researchers investigated ways to make small cell lung cancer more vulnerable to the immune system.
This story does not have two clearly opposing sides.
The IMpower133 and CASPIAN trials tested immunotherapy approaches to small cell lung cancer.
Researchers analyzed the trial data and found that patients with signs of more gamma delta T cells responded better to treatments.
The team tested small cell lung cancer cells and found that gamma delta T cells were more effective with tarlatamab or zoledronate.
- Five-year survival
- Fewer than 7 in 100 people survive small cell lung cancer for five years
- Immune cells studied
- Gamma delta T cells
- Drug tested with immune cells
- Tarlatamab
- Other drug tested
- Zoledronate
- Target marker
- BTN2A1
What people are saying
These cells may offer an alternative immune attack route for tumors that are able to evade conventional cancer-fighting immune cells, opening up new possibilities for treating a cancer that has seen few advances over the past decades
Strikingly, patients whose tumors contained more of these specialized immune cells often had better treatment outcomes
For patients with lower gamma delta T cell levels, therapies such as zoledronate may offer a way to boost their cancer-fighting immune cells and responsiveness to treatments